Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00855309 · ClinicalTrials.gov registry record · Phase 3
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT00855309 is a Phase 3 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 112 participants.
The verdict
NCT00855309, a Phase 3 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia.
Interventions
- DRUG acyclovir sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00855309
The ClinicalTrials.gov registry entry for NCT00855309 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which acyclovir sodium is the first listed.
NCT00855309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00855309 about?
NCT00855309 is a clinical study titled "Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia". RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with n...
What is the current status of trial NCT00855309?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2008-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00855309?
The interventions under investigation include: acyclovir sodium (DRUG).
Who is sponsoring clinical trial NCT00855309?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.